共 6 条
[1]
W oo SK,KangWK,Kwon K I.Pharmacok inetic and pharmacodyna-m ic modeling of the antiplatelet and card iovascu lar effects of cilostazolin healthy humans. C lin Pharmacol Ther . 2002
[2]
Bramer SL,Forbes WP,Mallikaarjun S.C ilostazol Pharmacokineticsafter Single andMultiple OralDoses in HealthyMales and Patientsw ithInterm ittent C laud ication Resulting from Peripheral Arterial D isease. C lin ical Pharmacokinet . 1999
[3]
Ak iyama H,Kudo S,Odom i M,et a.l H igh performance liqu idchromatograph ic procedure for the determ ination of a new antithrom-botic and vasod ilating agent,cilostazol,in human plasma. Journal of Chromatography . 1985
[4]
Fu CJ,Tata PN,Okada K,et a.l S imu ltaneous quantitative determ i-nation of cilostazol and its m etabolites in human plasma by h igh-per-formance liqu id chromatography. J Chromatogr B B iom ed Sci Ap-pl . 1999
[5]
Kambayash i J,L iu Y,Sun B,et a.l C ilostazol as a un ique antithrom-botic agent. Curr Pharm D es . 2003
[6]
Strandness ED,Dalman RL,Steve PS,et al.E ffect of cilostazol inpatients w ith interm ittent claud ication:a random ized,doub le-b lind,placebo-controlled study. Vascular and Endovascular Surgery . 2002